Kavindra Nath1,
Ting Liu1, David S. Nelson1, Hoon Choi2,
I-Wei Chen2, Dennis B. Leeper3, Rong Zhou1,
Jerry D. Glickson1
1Radiology,
University of Pennsylvania, Philadelphia, PA, United States; 2Materials
Science and Engineering, University of Pennsylvania, philadelphia, PA, United
States; 3Radiation Oncology, Thomas Jefferson University,
Philadelphia, PA, United States
Synopsis: In vivo 31P Magnetic Resonance Spectroscopy demonstrates that LNCaP prostate cancer xenografts treated with the putative monocarboxylate transporter (MCT) inhibitor, lonidamine (LND), exhibits a sustained and tumor-selective decrease in intracellular pH (pHi) from 6.87 0.04 to 6.40 0.07 (p = 0.02), extracellular pH (pHe) from 6.97 0.04 to 6.46 0.09 (p = 0.18) and tumor bioenergetics (βNTP/Pi) also decreased by 74.5 0.04% (p = 0.03) relative to the baseline level following LND administration. The decline of pHi, pHe and bioenergetics could be a critical parameter for thermosensitization and/or improving tumor response to alkylating agents.
Keywords